Mikhail Kalinichev

Company: Neurosterix

Job title: Head of Translational Science

Seminars:

Transforming the Translational Validity of Preclinical Psychosis Models: Moving Beyond Dopamine-Focused Assays to Study New Anti-Psychosis Drug Mechanisms & Demonstrate Clinically Relevant Readouts 9:00 am

Current psychosis research often relies on pharmacological challenges, such as administering stimulants (e.g., amphetamine) or NMDA receptor blockers (e.g., MK21, PCP) to healthy brains. While these methods model certain aspects of psychosis, they may not fully capture the broader alterations seen in the disorder. However, they remain among the best available tools. Recent advancements using…Read more

day: Pre-Conference Day

Animal Models of Psychosis – How to Show Antipsychotic Efficacy of Novel Drugs Based on Non-Dopaminergic Mechanisms 12:00 pm

Enhancing understanding of muscarinic agonism in animal psychosis models Overcoming differences in muscarinic expression patterns and coupling of different receptors between animals and humansRead more

day: Day Two